Clinical Trials Logo

Heart Transplant Rejection clinical trials

View clinical trials related to Heart Transplant Rejection.

Filter by:

NCT ID: NCT05772442 Not yet recruiting - Clinical trials for Heart Transplant Rejection

Cardiac Transplant Metabolomics

Start date: March 2023
Study type: Observational

Patient who received a heart transplant may develop organ rejection. Currently, an invasive biopsy of the heart needs to be performed to diagnose rejection. The purpose of this research study is to identify novel metabolic biomarkers that can be developed into a blood test that can identify signs of rejection without doing a heart biopsy.

NCT ID: NCT05732779 Not yet recruiting - Immune Suppression Clinical Trials

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.

NCT ID: NCT05205551 Recruiting - Clinical trials for Heart Transplant Rejection

Prospera Test Evaluation in Cardiac Transplant (ProTECT)

Start date: October 1, 2021
Study type: Observational [Patient Registry]

The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart transplantation.

NCT ID: NCT05184426 Active, not recruiting - Clinical trials for Antibody-mediated Rejection

MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)

Start date: April 1, 2021
Study type: Observational

Cross-sectional evaluation of antibody mediated injury in heart transplantation patients through a multimodal approach: electron microscopy, optic microscopy, immunohistochemistry techniques, transthoracic echocardiography, cardiac magnetic resonance, pressure guide wire, intravascular ultrasound

NCT ID: NCT05064462 Recruiting - Clinical trials for Heart Transplant Rejection

TTV Viral Load in Heart Transplant Recipients

Start date: March 3, 2022
Study type: Observational

This prospective, multicenter, non-interventional trial aims to study the association between TTV viral load and the occurrence of rejection or infection during the first year after transplantation. The TTV viral loads, taken once a month during the first year after the transplant, will be measured at the end of the study.

NCT ID: NCT04973943 Recruiting - Clinical trials for Heart Transplant Rejection

Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection

Start date: March 19, 2019
Study type: Observational

FreeDNA-CAR is a prospective, observational multicenter study, that will include a total of 200 adult heart transplant (HT) patients from 14 centers in Spain. Our main objective is to test donor-derived Cell-Free DNA (dd-cfDNA) against endomyocardial biopsy (EMB) for the diagnosis of acute cellular rejection.

NCT ID: NCT04921774 Active, not recruiting - Clinical trials for Heart Transplant Rejection

Research on Patients With Heart Transplantation

Start date: January 1, 2020
Study type: Observational

This trial was a single-center, prospective cohort study.The purpose of this clinical research is to evaluate the accuracy of combining multimodality MR Imaging with circulating exosomal miRNA expression to diagnose acute rejection in patients with heart transplantation´╝îthus it may be helpful for timely intervention to improve the patient's prognosis.

NCT ID: NCT04707872 Recruiting - Clinical trials for Heart Transplant Rejection

Trifecta-Heart cfDNA-MMDx Study

Start date: June 1, 2021
Study type: Observational

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

NCT ID: NCT04226521 Recruiting - Clinical trials for Cardiac Allograft Vasculopathy

Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Heart transplantation is a golden standard for the treatment of terminal heart failure. The major cause of death in late posttransplant period is cardiac allograft vasculopathy (CAV). This posttransplant complication develops slowly over several years, and when diagnosed either by conventional coronary angiography or due to graft failure, it is often too advanced and difficult to treat since it is diffuse coronary artery disease. Therefore, early prevention of CAV is a subject of major interest in the transplant cardiology. Since CAV is associated with immune factors, immunomodulatory therapeutic options, like extracorporeal photopheresis are lately being investigated. Unlike conventional coronary angiography, optical coherence tomography (OCT) is able to detect the development of CAV in the earliest phase, i.e. even in the first post-transplant year. In our study, we plan to investigate the prophylactic effect of extracorporeal photopheresis in the early development of cardiac graft vasculopathy detected by OCT.

NCT ID: NCT03833050 Completed - Clinical trials for Heart Transplant Rejection

The TOGETHER Project - Heart

Start date: December 7, 2017
Study type: Observational

The researchers are trying to develop a way to measure the risk of transplant rejection with a blood test.